SOUTH THAMES CHILDREN S CANCER NETWORK GROUP. REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014

Similar documents
SOUTH THAMES CHILDREN S AND YOUNG PEOPLE S CANCER NETWORK GROUP REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS

Coversheet for Network Site Specific Group Agreed Documentation. Diagnosis and Staging Protocol

North Thames Children and Young People s Cancer Network

Cancer of Unknown Primary (CUP) Protocol

Update on Management of Malignant Spinal Cord Compression. Heino Hugel Consultant in Palliative Medicine University Hospital Aintree

Faster Cancer Treatment Indicators: Use cases

Yorkshire and Humber Children and Young People s Cancer Network Referral, Diagnosis & Staging Protocol

WHAT ARE PAEDIATRIC CANCERS

1. The Initial Referral Protocol (09-7A-113)

PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE

New Surgical Oncology Clinic at Nationwide Children s Hospital

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

How a fully integrated Acute Oncology Service can benefit the busy medical unit

Cancer of Unknown Primary Service

Cancer of Unknown Primary (CUP)

Trust Guideline for the Pituitary Tumour / other Pituitary Emergency

High Intensity Chemotherapy Guidelines for Haematology Patients at ASPH

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

A Care Pathway exists for the management of neutropenic fever. Copies of the care pathway document are available in EAU, A&E, Deanesly and CHU.

West Midlands Sarcoma Advisory Group

PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY

South West Strategic Clinical Network Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services

Note: There are other bendamustine protocols, ensure this is the correct one for a given patient.

Metastatic Spinal Cord Compression (MSCC) Clinical guidelines and pathway

SIOP Europe the European Society for Paediatric Oncology European Network for Cancer Research in Children and Adolescents

LCA Lung Clinical Forum. 21 st October 2014

Medical Training Initiative Post Paediatric Oncology Fellow Retrieval. Job Description Lead Clinician Dr Emma Ross

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

CRITERIA FOR CREDENTIALLING A PAEDIATRIC HAEMATOLOGIST- ONCOLOGIST IN THE MALAYSIAN SPECIALIST REGISTER

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

Guideline for the referral to the Late Effects Multi Disciplinary Team

West Midlands Sarcoma Advisory Group

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2

Brain and Central Nervous System Cancers

This is a controlled document and therefore must not be changed

CP80 Version: V01. Acute Oncology Management Service Date approved: 8 th May 2015 Date ratified: 1 st June 2015 Review date: 1 st June 2017

This is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)

DA-EPOCH-R (Etoposide/Inpatient)

What is Acute Oncology? Kay McCallum Acute Oncology Advanced Nurse Practitioner John Radcliffe Hospital Oxford September 2015

Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS

MSCC CARE PATHWAYS & CASE STUDIES. By Michael Balloch Spine CNS

Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS

Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs

Brain and CNS tumours Presentation pathway

Subspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident

CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated

Spinal Cord Compression Diagnosis and Management. Information for Shared Care Centres and Community Staff

Children who are neutropenic and unwell, even if normothermic, should be assumed to have infection and be treated appropriately.

Shared Care & Survival CTYA SSCRG (Childhood Cancer Research Group)

Referral guide for acute oncology emergencies

ALL Phase 1 Induction (25-60 years)

PEER REVIEW VISIT REPORT (MULTI-DISCIPLINARY TEAM)

Clinical Guideline for the care of children with Hydrocephalus or blocked ventricular shunt

Atypical Teratoid / Rhabdoid tumours. Information for parents and carers

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Protocol for management of patients with pineal region tumours v1

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS

SAFE PAEDIATRIC NEUROSURGERY A Report from the SOCIETY OF BRITISH NEUROLOGICAL SURGEONS

Acute Oncology. Protocols & Competencies Acute Oncology Introduction

Integrated Care Pathway (ICP) for the. Management of clozapine COMMUNITY INITIATION

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Pediatric Oncology. Vlad Radulescu, MD

CARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS

Acute Oncology: Service Provision in Smaller Cancer Centres Ernie Marshall Clatterbridge Centre for Oncology

Guideline for the Acute Management of Stroke in Paediatric Patients with Sickle Cell Disease

R-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative

GUIDELINES FOR RADIOTHERAPY IN SPINAL CORD COMPRESSION THE CHRISTIE, GREATER MANCHESTER & CHESHIRE. Version:

Cancer Services Position & Recovery Plan June 2015

Testicular Germ Cell Cancer Explained

COSD & Source of Referral

Single Suspected Cancer Pathway Definitions pathway start date

Leukaemia 35% Lymphoma 14%

Delivering 62 Day GP Cancer Waits in a Complex Landscape. Hannah Marder Cancer Manager University Hospitals Bristol

There are a number of national guidelines and performance standards which support the implementation of a straight to CT pathway.

INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)

Lung cancer timed clinical pathways

Identifying distinguishing features of the MDC model within the five ACE projects

National Optimal Lung Cancer Pathway

Guidelines for the Immediate Management of Paediatric Patients with Sickle Cell Disease (SCD) and Acute Neurological Symptoms

NICE Quality Standards and COF

National Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer

Oncology. Access Center 24/7 access for referring physicians (866) 353-KIDS (5437)

Gamma Knife Radiosurgery A tool for treating intracranial conditions. CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop

Ambulatory lung biopsy: a new model for the NHS. Dr Sam Hare Barnet Hospital Royal Free London NHS Trust

Protocol for the Management of Neutropenic Sepsis in Adult Patients P

Ambulatory Emergency Care Pathways. Painless Obstructive Jaundice

2.07 Protocol Name: CHOP & Rituximab

Cancer of Unknown Primary (CUP)

Hodgkin s Lymphoma (Hodgkin s Disease, HD) PI HD-1 Protocol

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

3.1 Investigations for Patients Presenting with Haematuria Table 1

Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway

Appendix 4 Urology Care Pathways

Recognition & Treatment of Malignant Spinal Cord Compression Study Day

Health Board/Region: All-Wales

Vacancy list Pathway Boards

Transcription:

SOUTH THAMES CHILDREN S CANCER NETWORK GROUP REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014

Contents 1. Leukaemia Referral, Diagnostic and Staging Guidelines 2. Lymphoma Referral, Diagnostic and Staging Guidelines 3. Carcinoma and Melanoma Referral, Diagnostic and Staging Guidelines 4. Germ Cell and Gonadal Tumour Referral, Diagnostic and Staging Guidelines 5. Embryonal Tumours Referral, Diagnostic and Staging Guidelines 6. Bone Rumour Referral, Diagnostic and Staging Guidelines 7. Brain and CNS Referral, Diagnostic and Staging Guidelines 8. Late Effects Referral Guidelines

Suspected Leukaemia pathway (0 to 15 years and 364 days) A&E /other Trust Hospital- Paediatric Unit DIAGNOSIS/ SUSPICION OF LEUKAEMIA Clinical assessment Assess possibility of mediastinal mass, risk of tumour lysis, sepsis and coagulopathy Routine bloods: FBC, blood film, U&Es, Ca, PO4, LFTs, urate, LDH, coagulation screen, Gp&S Imaging: Chest X-ray. Do not do CT if mediastinal mass without prior discussion with RMH. Not required if FBC/Blood film abnormal. Do not sedate if any suspicion of mediastinal mass. After appropriate stabilisation contact Paediatric Oncology Registrar on call at RMH via hospital switchboard. Commence iv fluids and allopurinol prior to transfer. Transfuse as required. Consultant paediatrician on call to discuss possible diagnosis with family If patient unstable discuss with South Thames Retrieval Service Transfer to GOSH Patient 1yr Transfer to RMH Prepare & send appropriate transfer letters/ forms including copy of all investigation results (Imaging to be linked via IEP) Patient acutely unwell, WBC >100x10 9 /l + symptomatic (CNS signs, 02 requirement/active bleeding) or mediastinal mass Discuss with PICU. Transfer SGH Fax RMH leukaemia CNS to inform of Following transfer Diagnostic investigations: Bone marrow, trephine ± Lumbar puncture. Send peripheral blood immunophenotyping if blasts on blood film. Once confirmed, diagnosis, treatment plan and appropriate clinical trial to be discussed with family. Consultant letter to POSCU lead, GP & CCN team RMH Paediatric Leukaemia MDT meeting (weekly Wed) Review all new patient bone marrow morphology, immunophenotyping & cytogenetics. Management planned. Confirm trial registration. MDM proforma will be faxed to GP, Referrer, POSCU lead followed by letter

Suspected Lymphoma pathway (0 to 15 years and 364 days) A&E or other Trust Hospital- Paediatric Unit DIAGNOSIS/ SUSPICION OF LYMPHOMA Clinical assessment Routine bloods, Ultrasound, MRI and CT After appropriate stabilisation contact Paediatric Oncology Registrar on call at RMH via hospital switchboard. Consultant Paediatrician to discuss possible diagnosis with family. If patient unstable may require discussion with South Thames Retrieval Service Refer to GOSH Patient 1yr Refer to RMH Prepare & send appropriate transfer letters/ forms including copy of all investigation results ( Imaging to be linked via IEP) Patient acutely unwell or mediastinal mass. This is a medical emergency See Algorithm Transfer to SGH. Discuss with PICU prior to transfer Following transfer Fax RMH Shared Care Sister to inform of Complete staging investigations and confirm diagnosis. CT, PET Scan, MRI, Lumbar Puncture, Bone Marrow. Once confirmed, diagnosis, treatment plan and appropriate clinical trial to be discussed with family. Consultant letter to POSCU lead, GP & CCN team RMH Paediatric Tumour Board MDT meeting (weekly Thurs) Review all new patient imaging, and histology. Management planned. Confirm trial registration. MDM proforma will be faxed to GP, Referrer, POSCU lead followed by letter

Suspected Carcinoma and Melanoma pathway (0 to 15 years and 364 days) A&E or other Hospital- Paediatric Unit DIAGNOSIS/ SUSPICION OF CARCINOMA OR MELANOMA Clinical assessment Routine bloods, MRI and CT. Melanoma skin biopsy After appropriate stabilisation contact Paediatric Oncology Registrar on call at RMH via hospital switchboard. Consultant Paediatrician to discuss possible diagnosis with family. If patient unstable may require discussion with South Thames Retrieval Service Refer to GOSH Patient 1yr Refer to RMH Prepare & send appropriate transfer letters/ forms including copy of all investigation results (CD-ROM of imaging or image link via IEP) Patient acutely unwell Transfer to SGH. Discuss with RMH / PICU prior to transfer Following transfer Complete staging investigations and confirm diagnosis. Chest x-ray, restaging CT and MRI. Fax RMH Shared Care Sister to inform of Once confirmed, diagnosis, treatment plan and appropriate clinical trial to be discussed with family. Consultant letter to POSCU lead, GP & CCN team RMH MDT Discussion Review all new patient imaging, and histology. Management planned. Confirm trial registration. MDT proforma will be faxed to GP, Referrer, POSCU lead followed by letter

Suspected Germ Cell and Gonadal Tumours pathway (0 to 15 years and 364 days) A&E or other Trust Hospital- Paediatric Unit DIAGNOSIS/ SUSPICION OF GERM CELL OR GONADAL TUMOUR Clinical assessment Routine bloods, Ultrasound, MRI and CT After appropriate stabilisation contact Paediatric Oncology Registrar on call at RMH via hospital switchboard. Consultant Paediatrician to discuss possible diagnosis with family. If patient unstable may require discussion with South Thames Retrieval Service! Refer to GOSH Patient 1yr Refer to RMH Prepare & send appropriate transfer letters/ forms including copy of all investigation results (Imaging to be linked via IEP) Patient acutely unwell Transfer to SGH. Discuss with rmh / PICU prior to transfer Following transfer Complete staging investigation, tumour markers and confirm diagnosis. CT, MRI Fax RMH Shared Care Sister to inform of Once confirmed, diagnosis, treatment plan and appropriate clinical trial to be discussed with family. Consultant letter to POSCU lead, GP & CCN team RMH MDT meeting Review all new patient imaging, and histology. Management planned. Confirm trial registration. MDM proforma will be faxed to GP, Referrer, POSCU lead followed by letter

Suspected extra-cranial embryonal tumour pathway (0 to 15 years and 364 days) A&E / other Trust Hospital- Paediatric Unit DIAGNOSIS/ SUSPICION OF tumour (neuroblastoma, hepatoblastoma, Wilms tumour, germ cell tumours, rhabdomyosarcoma) Clinical assessment Routine bloods: FBC, U&Es, tumour Markers: AFP, B-HCG (for suspected germ cell tumours, liver tumours) urine for catecholamines for suspected neuroblastoma Imaging: Chest X-ray, CT/ MRI Contact Paediatric Oncology Registrar on call at RMH via hospital switchboard (Cordless 1450). Consultant paediatrician on call to discuss possible diagnosis with family If patient unstable discuss with South Thames Retrieval Service Refer to GOSH Patient 1yr Refer to RMH/SGH after discussion with RMH team Prepare & send appropriate transfer letters/ forms including copy of all investigation results Patient acutely unwell Transfer to SGH. Discuss with PICU prior to transfer Following transfer Fax RMH Shared Care Sister to inform of Diagnostic investigations: Biopsies at SGH for all tumours except liver tumours (King s college) Bilateral Bone marrow aspirates and trephine (suspected neuroblastoma, rhabdomyosarcoma) Central venous access Further staging investigations on confirmation of diagnosis RMH Solid Tumour MDT meeting (weekly Thu) Review all new patient imaging, histology and staging investigations. Plan management. Offer clinical trial if appropriate. MDM proforma will be faxed to GP, Referrer, POSCU lead and followed by letter

Suspected bone tumour pathway (0 to 24 years) A&E / other Trust Hospital- Paediatric / Adult Unit DIAGNOSIS / SUSPICION OF bone tumour Contact made with London Sarcoma Service (Royal National Orthopaedic Hospital). Tertiary s form sent to MDT co-ordinator. RNOH to request diagnostic tests required. Abnormal Breaking news. Consultant discuss with family Normal Communication from hospital to referrer. FUP regime is communicated if required Refer to GOSH Refer to Diagnostic Centre (Royal National Orthopaedic Hospital). Patient referred directly to RNOH. Trust transfer forms (if referred from Trust hospital). Send full letter and copy of notes. If imaging has been carried out, send imaging including plain films before transfer of patient. If biopsy has been performed, send pathology slides and blocks for review before transfer. Pre diagnostic Sarcoma MDT discussion (UCLH / RNOH). Sarcoma MDT held weekly, Friday morning. No joint MDT discussion with POSCU / referring Trust hospital. MDT report sent to the referring clinician at the Trust hospital and GP after MDT discussion. Arrival at diagnostic centre (Royal National Orthopaedic Hospital). DIAGNOSIS. Diagnostic investigations CT / MRI / US/ biopsy. Allocate key worker. Initial treatment inpatient clinical guidelines.

Suspected Brain or spinal cord tumour pathway (0 to 15 years and 364 days) A&E / other Trust Hospital- Paediatric Unit DIAGNOSIS/ SUSPICION OF BRAIN OR SPINAL CORD TUMOUR Clinical assessment (ABC plus neurology) Assess possibility of raised intracranial pressure (ICP) & G.C.S. Routine bloods: FBC, U&Es, Glucose, Coagulation Neuro-imaging: do not sedate patient if any concerns over raised ICP (An awake CT + contrast will demonstrate hydrocephalus/ most mass lesions if not possible to perform urgent awake MRI- if in doubt ask paediatric neurosurgery unit first) After appropriate stabilisation early discussion with regional paediatric neurosurgical unit via on-call neurosurgical registrar (switchboard- SGH/ Kings) for further advice/. If unstable may require discussion with South Thames Retrieval Service and/or time critical neurotransfer If possible ImageLink neuro-imaging via IEP. Exclusion of Brain/ spinal cord tumour! Arrange appropriate local follow up and communication. Confirmation (suspicion remains) of Brain/ spinal cord tumour! Consultant to discuss with patient/ family (Also inform local POSCU lead) Fax RMH Shared care coordinator to inform of Transfer to Regional Paediatric Neurosurgical Unit Mode of transfer will be based on patient s stability after discussion with neurosurgery and South Thames Retrieval Team if appropriate. Prepare & send appropriate transfer letters/ forms including copy of all investigation results (Image link via IEP) South Thames Paediatric Neuro-oncology MDM (weekly Friday) All new patients are discussed and management planned ( investigations and treatment may take place prior to MDM) MDM proforma will be sent to GP, Referrer, POSCU lead followed by letter

Long term follow-up clinic pathway RMH oncology-fu clinic Other sec/ tertiary centres A&E / other. Send treatment summary with details of chemotherapy, radiotherapy, surgery and adverse events during treatment. Note post bone marrow transplant patients need to be transferred 1 yr from end of treatment. Brain tumour patients may need earlier input by endocrinologist. All others are referred 5 years after end of treatment. Triage to Levels 1-3 Appropriate long term follow-up clinic Formulate care plan for follow-up. Brain Tumour - BTclinic seen by multi disciplinary team (MDT) Post Bone marrow transplant BMT follow up clinic seen by MDT All other patients seen in oncology late effects FU clinic & by MDT as required Brighton level 1-2 patients followed at late effects clinic at Brighton All patients are discussed at the once a month MDT meeting (2 nd Tues of the month) at the time of transfer to the oncology follow up clinic and again at transfer to adult clinic/ or transfer to Brighton. Prior to transfer to adult clinic a planned transition should take place over a number of years during which the patient is informed of his/her diagnosis, side effects and follow-up. A written summary and care plan should also be given to patient and adult follow up physician When patient is 18 years of age and has been off treatment for 5 years or more they should be transferred to the young adult clinic with a detailed follow-up care plan. Brighton patients should be transferred to the adult clinic at Brighton.